Scancell to speak at World Vaccine Congress Europe

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces Professor Lindy Durrant, Chief Executive Officer and Chief Scientific Officer of Scancell, will be presenting at the 2023 World Vaccine Congress Europe, taking place on 17-19 October in Barcelona, Spain.

Prof Lindy Durrant, Chief Executive Officer and Chief Scientific Officer of Scancell, commented: "Following the recent announcement of positive data from the first stage in our Phase 2 SCOPE trial with SCIB1 cancer vaccine for advanced melanoma, I am excited to join other leading experts in the field to discuss the ongoing clinical progress of our two lead cancer vaccine assets SCIB1/iSCIB-1+ and Modi-1 at this prestigious forum within the vaccine community."

The title, timing and location of the presentation are as follows:

Presentation title Clinical update on the DC targeting melanoma vaccine, SCIB1 and the Modi-1 vaccine targeting citrullination

Speaker Prof Lindy Durrant

Session date and time 11:00, 19 October 2023

Location Room 2

ModiFY is an open-label, multicohort, multicentre, adaptive Phase 1/2 trial of Modi-1 in patients with unresectable HGSOC, SCCHN, TNBC or RCC. The Modi-1 peptides are linked to AMPLIVANT®, a potent adjuvant which is the subject of a worldwide licensing and collaboration agreement with ISA Pharmaceuticals for the manufacturing, development, and commercialisation of Modi-1. Modi-1 stimulates CD4 T cells which may directly impact tumour growth; however, in some patients these T cells may need to be protected by CPIs if the tumour environment is highly immunosuppressive. Patients are therefore treated with Modi-1 alone or, if eligible for standard of care CPI, with Modi-1 plus a CPI.

Cohort 1 of the study confirmed the safety profile of a low dose of two citrullinated vimentin peptides. The objective for Cohort 2 of the trial was to assess the safety of the two citrullinated vimentin peptides plus an enolase peptide at a higher dose. Based on the safety data from Cohort 2, the ModiFY trial was expanded at this recommended Phase 2 dose for Modi-1 monotherapy in all four tumour types. In parallel, Cohort 3 recruited patients to receive low dose Modi-1 plus a CPI to assess safety of the combination prior to testing the higher dose of Modi-1 in Cohort 4.

Further information relating to the clinical trial can be found on the Company's website at https://www.scancell.co.uk and at https://clinicaltrials.gov/ct2/show/NCT05329532